Ventyx Biosciences IncNASDAQ:VTYX
- LAST PRICE4.3700
- TODAY'S CHANGE (%)-0.0800 (-1.7978%)
- Bid / Lots4.2100/ 1
- Ask / Lots4.5400/ 6
- Open / Previous Close4.4400 / 4.4500
- Day Range
- 52 Week Range
- Volume341,647
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VTYX |
|---|---|---|
| 09:32 ET | 3024 | 4.635 |
| 09:34 ET | 100 | 4.485 |
| 09:36 ET | 500 | 4.455 |
| 09:38 ET | 125 | 4.46 |
| 09:39 ET | 100 | 4.45 |
| 09:45 ET | 600 | 4.42 |
| 09:48 ET | 600 | 4.38 |
| 09:50 ET | 530 | 4.35 |
| 09:52 ET | 2917 | 4.3121 |
| 09:54 ET | 1950 | 4.3 |
| 09:56 ET | 3825 | 4.3001 |
| 09:57 ET | 15682 | 4.27 |
| 09:59 ET | 1510 | 4.2538 |
| 10:01 ET | 1710 | 4.29 |
| 10:03 ET | 910 | 4.28 |
| 10:06 ET | 500 | 4.29 |
| 10:08 ET | 3547 | 4.3 |
| 10:12 ET | 1451 | 4.3176 |
| 10:14 ET | 292 | 4.315 |
| 10:15 ET | 8420 | 4.33 |
| 10:17 ET | 745 | 4.35 |
| 10:19 ET | 2794 | 4.37 |
| 10:21 ET | 2454 | 4.4 |
| 10:26 ET | 1136 | 4.39 |
| 10:28 ET | 1300 | 4.38 |
| 10:30 ET | 500 | 4.39 |
| 10:32 ET | 375 | 4.4 |
| 10:33 ET | 100 | 4.4 |
| 10:35 ET | 500 | 4.39 |
| 10:39 ET | 1337 | 4.4 |
| 10:42 ET | 300 | 4.41 |
| 10:44 ET | 500 | 4.4 |
| 10:48 ET | 2500 | 4.39 |
| 10:50 ET | 100 | 4.39 |
| 10:51 ET | 644 | 4.3812 |
| 10:55 ET | 3500 | 4.41 |
| 10:57 ET | 300 | 4.4 |
| 11:02 ET | 1102 | 4.39 |
| 11:04 ET | 1561 | 4.41 |
| 11:06 ET | 804 | 4.42 |
| 11:09 ET | 100 | 4.42 |
| 11:11 ET | 6990 | 4.4101 |
| 11:15 ET | 1000 | 4.435 |
| 11:18 ET | 192 | 4.43 |
| 11:22 ET | 100 | 4.44 |
| 11:26 ET | 2718 | 4.455 |
| 11:27 ET | 3079 | 4.46 |
| 11:29 ET | 100 | 4.49 |
| 11:33 ET | 100 | 4.48 |
| 11:36 ET | 800 | 4.4857 |
| 11:38 ET | 900 | 4.46 |
| 11:42 ET | 100 | 4.45 |
| 11:44 ET | 1300 | 4.45 |
| 11:45 ET | 3323 | 4.46 |
| 11:49 ET | 1700 | 4.46 |
| 11:51 ET | 100 | 4.47 |
| 11:56 ET | 100 | 4.455 |
| 12:02 ET | 500 | 4.46 |
| 12:03 ET | 520 | 4.46 |
| 12:05 ET | 300 | 4.48 |
| 12:07 ET | 1809 | 4.51 |
| 12:09 ET | 4500 | 4.52 |
| 12:12 ET | 2200 | 4.5001 |
| 12:14 ET | 1121 | 4.49 |
| 12:16 ET | 300 | 4.49 |
| 12:18 ET | 200 | 4.48 |
| 12:20 ET | 2193 | 4.5 |
| 12:21 ET | 221 | 4.5 |
| 12:23 ET | 200 | 4.49 |
| 12:25 ET | 200 | 4.5 |
| 12:27 ET | 200 | 4.49 |
| 12:32 ET | 400 | 4.49 |
| 12:34 ET | 200 | 4.49 |
| 12:36 ET | 300 | 4.48 |
| 12:39 ET | 2357 | 4.49 |
| 12:41 ET | 100 | 4.5 |
| 12:43 ET | 500 | 4.51 |
| 12:45 ET | 600 | 4.51 |
| 12:48 ET | 325 | 4.5 |
| 12:50 ET | 300 | 4.5 |
| 12:52 ET | 200 | 4.49 |
| 12:56 ET | 200 | 4.48 |
| 12:57 ET | 300 | 4.46 |
| 12:59 ET | 200 | 4.46 |
| 01:03 ET | 300 | 4.45 |
| 01:06 ET | 200 | 4.45 |
| 01:08 ET | 1700 | 4.45 |
| 01:10 ET | 633 | 4.45 |
| 01:12 ET | 400 | 4.456 |
| 01:14 ET | 889 | 4.46 |
| 01:15 ET | 200 | 4.45 |
| 01:17 ET | 136 | 4.46 |
| 01:19 ET | 300 | 4.46 |
| 01:21 ET | 417 | 4.465 |
| 01:24 ET | 900 | 4.45 |
| 01:26 ET | 100 | 4.46 |
| 01:28 ET | 605 | 4.45 |
| 01:30 ET | 500 | 4.45 |
| 01:32 ET | 200 | 4.45 |
| 01:33 ET | 953 | 4.45 |
| 01:35 ET | 400 | 4.45 |
| 01:37 ET | 700 | 4.45 |
| 01:39 ET | 400 | 4.445 |
| 01:42 ET | 2068 | 4.45 |
| 01:44 ET | 1201 | 4.465 |
| 01:46 ET | 200 | 4.45 |
| 01:50 ET | 174 | 4.45 |
| 01:53 ET | 912 | 4.46 |
| 01:55 ET | 100 | 4.45 |
| 01:57 ET | 800 | 4.465 |
| 02:02 ET | 900 | 4.46 |
| 02:06 ET | 400 | 4.44 |
| 02:09 ET | 100 | 4.43 |
| 02:11 ET | 585 | 4.43 |
| 02:13 ET | 1094 | 4.41 |
| 02:15 ET | 600 | 4.41 |
| 02:18 ET | 1163 | 4.4 |
| 02:20 ET | 100 | 4.39 |
| 02:22 ET | 1904 | 4.41 |
| 02:24 ET | 100 | 4.405 |
| 02:26 ET | 1901 | 4.4 |
| 02:29 ET | 700 | 4.39 |
| 02:31 ET | 1323 | 4.375 |
| 02:33 ET | 2130 | 4.374 |
| 02:38 ET | 280 | 4.36 |
| 02:42 ET | 1970 | 4.368 |
| 02:44 ET | 1330 | 4.35 |
| 02:45 ET | 3594 | 4.39 |
| 02:47 ET | 980 | 4.3888 |
| 02:49 ET | 100 | 4.385 |
| 02:51 ET | 578 | 4.38 |
| 02:54 ET | 2362 | 4.37 |
| 02:56 ET | 300 | 4.36 |
| 03:00 ET | 1684 | 4.37 |
| 03:02 ET | 100 | 4.36 |
| 03:03 ET | 2224 | 4.38 |
| 03:05 ET | 1308 | 4.39 |
| 03:07 ET | 200 | 4.38 |
| 03:09 ET | 200 | 4.385 |
| 03:12 ET | 1433 | 4.38 |
| 03:14 ET | 100 | 4.37 |
| 03:16 ET | 200 | 4.37 |
| 03:18 ET | 1405 | 4.38 |
| 03:20 ET | 1572 | 4.3801 |
| 03:21 ET | 100 | 4.385 |
| 03:23 ET | 1116 | 4.375 |
| 03:25 ET | 306 | 4.38 |
| 03:27 ET | 726 | 4.375 |
| 03:30 ET | 219 | 4.375 |
| 03:32 ET | 100 | 4.37 |
| 03:34 ET | 200 | 4.3701 |
| 03:36 ET | 200 | 4.37 |
| 03:38 ET | 513 | 4.375 |
| 03:39 ET | 3764 | 4.41 |
| 03:41 ET | 2145 | 4.41 |
| 03:43 ET | 2136 | 4.4297 |
| 03:45 ET | 400 | 4.43 |
| 03:48 ET | 3799 | 4.43 |
| 03:50 ET | 1500 | 4.415 |
| 03:52 ET | 5800 | 4.41 |
| 03:54 ET | 3654 | 4.4 |
| 03:56 ET | 11145 | 4.37 |
| 03:57 ET | 7166 | 4.365 |
| 03:59 ET | 64325 | 4.37 |
May 20, 2024
May 17, 2024
May 16, 2024
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences, from 4:05PM ET on Thursday May 16, 2024 by Dow Jones
4:05PM ET on Thursday May 16, 2024 by Dow JonesPress Release: Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer, from 8:00AM ET on Thursday May 16, 2024 by Dow Jones
8:00AM ET on Thursday May 16, 2024 by Dow JonesVentyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer, from 8:00AM ET on Thursday May 16, 2024 by Dow Jones
8:00AM ET on Thursday May 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ventyx Biosciences Inc | 308.1M | -1.3x | --- |
Atea Pharmaceuticals Inc | 308.3M | -1.9x | --- |
Solid Biosciences Inc | 299.0M | -2.0x | --- |
Q32 Bio Inc | 310.5M | -1.0x | --- |
Replimune Group Inc | 320.6M | -1.6x | --- |
ESSA Pharma Inc | 283.5M | -10.2x | --- |
Company Information
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Contact Information
- Headquarters
- 12790 El Camino Real, Suite 200SAN DIEGO, CA, United States 92130
- Phone
- 858-945-2393
- Fax
- 302-655-5049
Executives
- Executive Chairperson of the Board
- Sheila Gujrathi
- President, Chief Executive Officer, Founder, Director
- Raju Mohan
- Chief Financial Officer
- Martin Auster
- Chief Operating Officer
- Matthew Moore
- Chief Scientific Officer
- John Nuss
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $308.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.24 |
Book Value | $4.12 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
